Results from the Phase 3 VISIONARY trial showed a 97.1% reduction in the risk of a composite kidney outcome event of kidney ...
SIMTRIYO is the first and only norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) approved for the treatment of ADHD in adults and pediatric patients aged 6 years and older weighing at ...
Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). The ...
Ulefnersen demonstrated a statistically significant improvement versus placebo on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the ...
June 17, 2019 – Princeton, NJ - Otsuka America Pharmaceutical, Inc. (Otsuka) has commissioned an innovative and interactive digital art installation, "Light the Way", which is currently on display at ...
Otsuka is a healthcare company driven by our purpose and defined by our beliefs.
At Otsuka, we’re working to lead an industry-wide shift in the ways caregivers are valued and supported. We are committed to caring for caregivers—standing with them, the way they stand with their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results